Coya Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Coya Therapeutics Common
COYA Stock   4.71  0.03  0.63%   
Coya Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Coya Therapeutics' valuation are provided below:
Gross Profit
-9.7 M
Market Capitalization
98.6 M
Enterprise Value Revenue
17.7391
Revenue
4 M
Earnings Share
(1.11)
We have found one hundred six available fundamental signals for Coya Therapeutics Common, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Coya Therapeutics Common prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road.

Coya Therapeutics Total Revenue

2.63 Million

Check Coya Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Coya Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 23.4 K, Interest Expense of 2.9 M or Selling General Administrative of 5.4 M, as well as many indicators such as Price To Sales Ratio of 14.85, Dividend Yield of 0.0 or PTB Ratio of 1.85. Coya financial statements analysis is a perfect complement when working with Coya Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Coya Stock
Check out the analysis of Coya Therapeutics Correlation against competitors.

Coya Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets53.5 M51 M17.6 M
Slightly volatile
Total Current Liabilities3.1 M4.4 M1.5 M
Slightly volatile
Accounts Payable1.3 M1.8 M791.3 K
Slightly volatile
Cash46.3 M44.1 M15.7 M
Slightly volatile
Cash And Short Term Investments46.3 M44.1 M15.7 M
Slightly volatile
Net Receivables798.2 K840.2 K1.5 M
Slightly volatile
Common Stock Shares Outstanding9.8 M17.5 M5.8 M
Slightly volatile
Liabilities And Stockholders Equity53.5 M51 M17.6 M
Slightly volatile
Non Current Liabilities Total1 M1.1 M1.3 M
Pretty Stable
Other Current Assets6.3 M6 M1.2 M
Slightly volatile
Other Stockholder Equity97 M92.4 M19.7 M
Slightly volatile
Total Liabilities6.3 M5.5 M2.7 M
Slightly volatile
Total Current Assets53.5 M51 M17.5 M
Slightly volatile
Capital Stock1.4 K1.5 K6.7 M
Slightly volatile
Net Working Capital48.9 M46.6 M15.9 M
Slightly volatile
Common Stock2 K1.9 K613
Slightly volatile
Non Currrent Assets Other46.5 M44.3 M10 M
Slightly volatile
Deferred Long Term Liabilities662.5 K1.3 M373.3 K
Slightly volatile
Property Plant Equipment85.6 K84 K111.6 K
Slightly volatile
Short and Long Term Debt Total10.4 M11.7 M12.7 M
Slightly volatile
Long Term Debt10.4 M11.7 M12.7 M
Slightly volatile
Current Deferred Revenue708.6 K763.5 K896.7 K
Slightly volatile
Short Term Debt579.1 K651.5 K711.1 K
Slightly volatile
Short Term Investments30.6 B34.5 B37.6 B
Slightly volatile

Coya Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization23.4 K24.6 K464.6 K
Slightly volatile
Interest Expense2.9 M2.8 M793.2 K
Slightly volatile
Selling General Administrative5.4 M10.2 M2.8 M
Slightly volatile
Selling And Marketing Expenses10.7 B10.2 B3.3 B
Slightly volatile
Other Operating Expenses25.1 M23.9 M6.5 M
Slightly volatile
Research Development14.4 M13.7 M3.4 M
Slightly volatile
Total Operating Expenses6.3 M10.3 M3.3 M
Slightly volatile
Cost Of Revenue14.3 M13.6 M2.9 M
Slightly volatile
Reconciled Depreciation27 K31.5 K19.7 K
Slightly volatile

Coya Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation25.2 K31.5 K19.5 K
Slightly volatile
End Period Cash Flow46.3 M44.1 M15.7 M
Slightly volatile
Change To Netincome3.9 M3.7 M1.3 M
Slightly volatile
Change To Liabilities611.7 K972.1 K383.6 K
Slightly volatile
Stock Based Compensation3.2 M3.1 M754.2 K
Slightly volatile
Begin Period Cash Flow39.4 M37.5 M13.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio14.8522.1113.9529
Slightly volatile
Days Sales Outstanding81.9786.28390
Slightly volatile
Average Payables1.1 M1.2 M1.3 M
Slightly volatile
Stock Based Compensation To Revenue0.360.670.2243
Slightly volatile
Capex To Depreciation6.787.638.3298
Slightly volatile
EV To Sales8.3612.47.8889
Slightly volatile
Payables Turnover3.916.723.2036
Slightly volatile
Sales General And Administrative To Revenue1.522.251.4436
Slightly volatile
Research And Ddevelopement To Revenue1.743.011.3056
Slightly volatile
Cash Per Share1.662.262.8199
Slightly volatile
Days Payables Outstanding10156.18131
Slightly volatile
Income Quality0.640.620.6243
Slightly volatile
Current Ratio9.9413.3215.5362
Slightly volatile
Receivables Turnover2.264.381.3358
Slightly volatile
Capex Per Share0.01660.01860.0204
Slightly volatile
Average Receivables3.3 M3.7 M4 M
Slightly volatile
Revenue Per Share0.450.270.5424
Slightly volatile
Interest Debt Per Share1.231.170.4576
Slightly volatile
Debt To Assets1.231.391.5168
Slightly volatile
Operating Cycle81.9786.28390
Slightly volatile
Days Of Payables Outstanding10156.18131
Slightly volatile
Ebt Per Ebit1.131.041.0503
Very volatile
Long Term Debt To Capitalization2.272.552.7858
Slightly volatile
Total Debt To Capitalization2.272.552.7858
Slightly volatile
Quick Ratio9.9413.3215.5362
Slightly volatile
Net Income Per E B T1.131.11.0929
Pretty Stable
Cash Ratio9.0911.5315.1166
Slightly volatile
Days Of Sales Outstanding81.9786.28390
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.830.931.0168
Slightly volatile
Fixed Asset Turnover73.2582.8989.5543
Slightly volatile
Debt Ratio1.231.391.5168
Slightly volatile
Price Sales Ratio14.8522.1113.9529
Slightly volatile
Asset Turnover0.120.09220.137
Slightly volatile

Coya Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap30.9 M42.4 M33.9 M
Slightly volatile
Enterprise Value32 M48.7 M32.5 M
Slightly volatile

Coya Fundamental Market Drivers

Coya Upcoming Events

3rd of April 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
3rd of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Coya Therapeutics Financial Statements

Coya Therapeutics stakeholders use historical fundamental indicators, such as Coya Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Coya Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Coya Therapeutics' assets and liabilities are reflected in the revenues and expenses on Coya Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Coya Therapeutics Common. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue763.5 K708.6 K
Total Revenue4.1 M2.6 M
Cost Of Revenue13.6 M14.3 M
Stock Based Compensation To Revenue 0.67  0.36 
Sales General And Administrative To Revenue 2.25  1.52 
Research And Ddevelopement To Revenue 3.01  1.74 
Revenue Per Share 0.27  0.45 
Ebit Per Revenue(5.58)(5.86)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
When determining whether Coya Therapeutics Common offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Coya Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Coya Therapeutics Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Coya Therapeutics Common Stock:
How To Invest In Coya
Details
Is Coya Stock a good investment?
Details
What is Coya Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Coya Therapeutics Correlation against competitors.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Coya Therapeutics. Projected growth potential of Coya fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Coya Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(1.11)
Revenue Per Share
0.24
Quarterly Revenue Growth
(0.95)
Return On Assets
(0.37)
Return On Equity
(0.62)
The market value of Coya Therapeutics Common is measured differently than its book value, which is the value of Coya that is recorded on the company's balance sheet. Investors also form their own opinion of Coya Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Coya Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Coya Therapeutics' market value can be influenced by many factors that don't directly affect Coya Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between Coya Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Coya Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Coya Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY